read all about it inside the ewma university conference model

More documents

Recommendations

Info

EWMA Position Document 2008 Hard-to-heal wounds a holistic approach Editor: Christine Moffatt The seventh European Wound Management Association position document will be launched in May 2008 at the EWMA congress ‘Wound Management · Wound Healing – Responsibility and Actions’, to be held in Lisbon, Portugal, 14-16 May 2008. The document will be available in English, French, German, Italian and Spanish, and can be downloaded from www.ewma.org It is possible to obtain permission to translate the EWMA Position Documents into other languages. Please contact EWMA Business Office. Previous Position Documents: 36 EWMA For further details contact MEP Ltd, 53 Hargrave Road, London N19 5SH. www.mepltd.co.uk or EWMA Business Office, Congress Consultants, Martensens Allé 8, 1828 Frederiksberg, Denmark Tel: +45 7020 0305 Fax: +45 7020 0315 ewma@ewma.org We regret to inform our readers that the references published for the paper entitled Treatment of chronic wounds with autologous platelet-rich plasma in EWMA Journal, Vol 8, No 2 are incorrect. The correct references are listed below. References: 1. Davidson JM. Growth factors: the promise and the problems. Int J Low Extrem Wounds 2007;6:8-10. 2. Pietrzak WS, Eppley BL. Platelet rich plasma: biology and new technology. J Craniofac Surg 2005;16: 1043-54. 3. Knighton DR, Ciresi K, Fiegel VD, et al. Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg 1986; 204: 322-0. 4. Crovetti G, Martinelli G, Issi M, et al. Platelet gel for healing cutaneous chronic wounds. Transus Apher Sci 2004; 30: 145-1. 5. McAleer JP, Kaplan E, Persich G. Efficacy of concentrated autologous platelet-derived growth factors in chronic lower-extremity wounds. J Am Podiatr Med Assoc 2006; 96 :482-8. 6. Steenvorde P, van Doorn LP, Naves C., et al. Use of autologous platelet-rich fibrin on hard-to-heal wounds. J Wound Care 2008; 17: 60-3. 7. Eppley BL, Woodall JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg 2004; 114: 1502-8. 8. Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Repair Regen 1996; 4: 411-420. 9. Gürgen M. The TIME wound management system used on 100 patients at a wound clinic. In: Dealey C, editor; Proceedings of the 17th Conference of the European Wound Management Association; 2007, May 2-4; Glasgow, UK. European Wound Healing Association; 2007. p.133. 10. Senet P, Bon FX, Benbunan M, et al. Randomized trial and local biological effect of autologous platelets used as adjuvant therapy for chronic venous leg ulcers. J Vasc Surg 2003; 38: 1342-8. 11. Reutter H, Bort S, Jung MF, et al. Questionable effectiveness of autologous platelet growth factors (PDWHF) in treatment of venous ulcers of the leg. Hautarzt 1999; 50: 859-65. 12. Falanga V, Eaglstein WH, Bucalo B, et al. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol 1992; 18: 604-6. 13. Coerper S, Köveker G, Flesch I, et al. Ulcus cruris venosum: surgical debridement, antibiotic therapy and stimulation with thrombocytic growth factors. Langenbecks Arch Chir 1995; 380: 102-7. 14. Herouy Y, Mellios P, Bandemir E, et al. Autologous platelet-derived wound healing factor promotes angiogenesis via alphavbeta3-integrin expression in chronic wounds. Int J Molecular Med 2000; 6: 515-9. 15. Mazzucco L, Medici D, Serra M. The use of autologous platelet gel to treat difficult-to-heal wounds: a pilot study. Transfusion 2004; 44: 1013-18 16. Margolis DJ, Kantor J, Santanna J. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2001; 24: 483-8. 17. Nelson EA, Prescott RJ, Harper DR, et al. A factorial, randomized trial of pentoxifylline or placebo, four-layer or single-layer compression, and knitted viscose or hydrocolloid dressing for venous ulcers. J Vasc Surg 2007; 45: 134-41. EWMA Journal 2008 vol 8 no 3
At dressing changes, pain matters most �� Ask patients with chronic wounds for their views on pain and you’ll fi nd that one of their biggest worries is dressing changes. In a survey of 2018 patients1 , 40.3% said pain at dressing change was the most devestating part of living with a wound. Since 53.8% of all respondents also reported pain ’frequently’ or ’most of the time’ during dressing changes, this is a signifi cant problem. The solution? In a separate survey, 93% of 3034 patients said they preferred dressings with Safetac ® technology because they are less painful2 . The new 2008 WUWHS Principles of Best Practice guidelines also refer to Safetac technology for atraumatic dressing removal. Which means you can make your patients feel a lot better by choosing the dressings that are less painful2 and that professionals prefer3 – dressings with patented Safetac technology. For more information about Safetac technology, please visit www.safetac.com Patented Safetac ® technology is available exclusively on Mepilex ® wound dressings, Mepitel ® and other selected Mölnlycke Health Care dressings. The Mölnlycke Health Care name and logo, Safetac ® , Mepilex ® wound dressings and Mepitel ® are registered trademarks of Mölnlycke Health Care AB. Mölnlycke Health Care AB (publ.), Box 13080, SE-402 52 Göteborg, Sweden. Phone + 46 31 722 30 00. www.molnlycke.com �� Order your full copy of the new 2008 WUWHS guidelines at www.molnlycke.com 1. Price P et al. Findings of an International Pain Survey. Submitted to International Wound Journal 2008 2. White R., Wounds UK 2008; Vol 4, No 1 3. Data on fi le
Page 1 and 2: READ ALL ABOUT IT INSIDE Volume 8 N
Page 3 and 4: 3 Editorial Carol Dealey Science, P
Page 5 and 6: EWMA2008 Presented at the 18 th Con
Page 7 and 8: See what Gelling Foam can do for yo
Page 9 and 10: Biatain Ibu is part of the Biatain
Page 13 and 14: Table 2. Semi-quantitative growth o
Page 15 and 16: Limitations of the Study: The bacte
Page 19 and 20: Table 3. Therapy characteristics an
Page 21 and 22: AMD Infection Control Products Pow
Page 27 and 28: Figure 2 The diagram is organized i
Page 29 and 30: SOCIO-ECONOMICAL ASPECTS In order t
Page 31 and 32: After this study, a new consensus d
Page 33 and 34: of a risk assessment tool is recomm
Page 35: were searched and manufacturers of
Page 39 and 40: English English Serbian Scandinavia
Page 41 and 42: WHY SHOULD YOU UNDERTAKE THE EWMA U
Page 43 and 44: The innovative WoundASSIST ® TNP s
Page 45: URGO R A N G E URGO R A N G E NEW C
Page 48 and 49: The exhibition was well-visited as
Page 50 and 51: Pedro Pacheco, Portugal Anna Marie
Page 52 and 53: Corporate A Coloplast Holtedam 1-3
Page 54 and 55: Conferences The man with the red ca
Page 56 and 57: Conferences Conference Calendar Con
Page 58 and 59: 58 Cooperating Organisations Danish
Page 60: 3 Editorial Carol Dealey Science, P

read all about it inside the ewma university conference model

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?